Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial
Biomolecules · 01.09.2025 · 15 (9) · 1268
DOI: 10.3390/biom15091268 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Biomolecules, online erschienen am 01.09.2025. Verfasst von Rosanna Squitti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Zinc, Cognition, Alzheimer Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer Association, Italian Ministry of Health, Alzheimer’s Association Part the Cloud: Translational Research Funding for Alzheimer’s Disease (PTC).
Abstract (Originalsprache)
Dysregulation contributes to Alzheimer’s disease (AD) pathophysiology. Zinc therapy promotes enterocyte copper sequestration, potentially reducing systemic copper. Individual biological responses may vary.
Methods
ZINCAiD was a 24-week, randomized, double-blind, placebo-controlled phase II trial assessing zinc therapy in individuals with mild cognitive impairment (MCI) due to AD (EudraCT No.: 2019-000604-15; registered on 26 March 2020). Participants were randomized 2:1 to receive elemental zinc (135 mg/day for 12 weeks, then 65 mg/day) or placebo. Ceruloplasmin was measured at predefined intervals for safety monitoring, blinded to the investigators. Post hoc, “Zinc Responders” were defined by ≥20% reduction in ceruloplasmin at week 12. The primary cognitive endpoint was the Cognitive Composite 2 scale (CC2); secondary endpoints included MMSE and CDR-Sob.
Findings
Of the 48 participants randomized, 9 discontinued, primarily due to unrelated clinical deterioration; 39 had complete ceruloplasmin data. Two serious adverse events occurred in the Placebo group. Mild gastrointestinal symptoms occurred in eight participants, with only four leading to dropout. In the primary zinc vs. placebo analysis, no significant differences emerged in cognitive outcomes. A post hoc exploratory analysis stratified participants by pharmacodynamic response: 12 individuals with MCI due to AD (31%) met the criteria for “Zinc Responder,” defined by ≥20% reduction in serum ceruloplasmin at week 12. Only Zinc Responders maintained cognitive stability over 24 weeks, whereas the combined group of Zinc Non-Responders and placebo-treated participants showed a significant decline. For the composite cognitive score (CC2), the interaction between visit and response group was significant (p = 0.030), with deterioration observed only in the Non-Responder + Placebo group (Δ = –2.72, p < 0.0001 vs. –0.71, p = 0.35 in Responders). Similar patterns were observed for CDR-Sob (interaction p = 0.017) and MMSE (trend p = 0.09).
Interpretation
Zinc therapy stabilized cognition in a pharmacodynamically defined MCI subgroup. These exploratory findings suggest serum ceruloplasmin as a feasible biomarker of target engagement. Larger trials are needed for confirmation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.
- Department of Laboratory Science, Research and Development Division, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy.
- Department of Theoretical and Applied Sciences (DISTA), eCampus University, 22100 Como, Italy.
- Neurology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, 34127 Trieste, Italy.
- Neurology Clinic, Department of Medicine, Surgery and Health Sciences, Azienda Sanitaria Universitaria Giuliano Isontina, 34148 Trieste, Italy.
- Service of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.
ORCID-Profile: Rosanna Squitti, Alberto Benussi, Silvia Fostinelli, Andrea Geviti, Jasmine Rivolta, Alessandra Micera, Roberta Ghidoni, Alberto Granzotto, Stefano L Sensi, Barbara Borroni
Förderung
- Alzheimer Association
- Italian Ministry of Health
- Alzheimer’s Association Part the Cloud: Translational Research Funding for Alzheimer’s Disease (PTC)
- EudraCT
Zitieren
APA
Squitti, R., Benussi, A., Fostinelli, S., Geviti, A., Rivolta, J., Ventriglia, M., Micera, A., Rongioletti, M., Ghidoni, R., Santilli, M., Granzotto, A., Albanese, A., Binetti, G., Sensi, S. L., & Borroni, B. (2025). Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial. Biomolecules, 15(9), 1268. https://doi.org/10.3390/biom15091268
Vancouver
Squitti R, Benussi A, Fostinelli S, Geviti A, Rivolta J, Ventriglia M, et al. Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial. Biomolecules. 2025;15(9):1268. doi:10.3390/biom15091268
BibTeX
@article{Squitti2025,
author = {Squitti, Rosanna and Benussi, Alberto and Fostinelli, Silvia and Geviti, Andrea and Rivolta, Jasmine and Ventriglia, Mariacarla and Micera, Alessandra and Rongioletti, Mauro and Ghidoni, Roberta and Santilli, Matteo and Granzotto, Alberto and Albanese, Alberto and Binetti, Giuliano and Sensi, Stefano L and Borroni, Barbara},
title = {Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {9},
pages = {1268},
doi = {10.3390/biom15091268}
}
EUVIMED